E098 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542).

Robert Landewe, Desiree van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Bengt Hoepken, Karen Thomas, Lianne S Gensler. E098 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542). Rheumatology. 2019 Apr 1; 58(Supplement_3).

2019
https://researcherprofiles.org/profile/79292867

Robert Landewe, Desiree van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Bengt Hoepken, Karen Thomas, Lianne S Gensler